| Species |
Porcine |
| Protein Construction |
FGF-basic (Pro171-Ser316)
Accession # A0A287ADF0 |
|
| Purity |
≥ 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 1.0 ng/ml, measured by a cell proliferation assay using BALB/3T3 cells, corresponding to a specific activity of > 1.0 ×106 units/mg. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
16.4 kDa |
| Apparent Molecular Weight |
20.1 kDa, on SDS-PAGE under reducing conditions |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4 |
| Reconstitution |
Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O up to 100 μg/ml |
| Storage & Stability |
Upon receiving, this product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable up to 1 week at 4 °C or up to 3 months at -20 °C or below. Avoid repeated freeze-thaw cycles. |
The ED50 as determined by a cell proliferation assay using BALB/3T3 cells is 0.1310 ng/ml
Lane 1: 2 µg of FGF-basic，Porcine under reducing condition (R)
Lane 2: 2 µg of FGF-basic，Porcine non-reducing condition (NR) (N)
The purity is greater than 95% as analyzed by SDS-PAGE
| Target Background |
Fibroblast Growth Factor-basic (FGF-basic), also known as FGF-2, is a pleiotropic cytokine. FGF-basic is produced by fibroblasts, and vascular cells. It regulates a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. FGF-basic can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. |
| Synonyms |
Fibroblast Growth Factor-basic; FGF-2; BFGF; FGFB; HBGF-2; bFGF; Prostatropin |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
